Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Pioglitazone418 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49394 | 35765391 | Cureus | The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A49572 | 35709779 | Acta Gastroenterol Belg | Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ? | 2022 | Details |
| A49933 | 35589613 | Diabetes Obes Metab | Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. | 2022 | Details |
| A49970 | 35578445 | Hepatol Commun | Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. | 2022 | Details |
| A49988 | 35569886 | Endocr Pract | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). | 2022 | Details |
| A50088 | 35531719 | Zhongguo Zhong Yao Za Zhi | [Mechanism of Tibetan medicine Ershiwuwei Songshi Pills in regulating intestinal flora and improving non-alcoholic steatohepatitis]. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50386 | 35409028 | Int J Mol Sci | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50721 | 35287643 | BMC Endocr Disord | Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A51462 | 33989565 | Cell Chem Biol | Endogenous vitamin E metabolites mediate allosteric PPARγ activation with unprecedented co-regulatory interactions. | 2021 | Details |
| A52166 | 30481177 | PLoS One | A metabolome-wide characterization of the diabetic phenotype in ZDF rats and its reversal by pioglitazone. | 2018 | Details |
| A52218 | 29998913 | J Atheroscler Thromb | Pathophysiology of Diabetic Dyslipidemia. | 2018 | Details |
| A52589 | 25294945 | Diabetes | Anti-CD44 antibody treatment lowers hyperglycemia and improves insulin resistance, adipose inflammation, and hepatic steatosis in diet-induced obese mice. | 2014 | Details |
| A52751 | 22471957 | Cardiovasc Hematol Agents Med Chem | PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations. | 2012 | Details |
| A52753 | 22428554 | J Immunotoxicol | Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance. | 2012 | Details |
| A52934 | 19349323 | Circulation | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. | 2009 | Details |
| A52979 | 18445783 | J Pharmacol Exp Ther | Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in Zucker diabetic fatty rats. | 2008 | Details |